• slide
  • slide

Immuno-Oncology

At TriStar we understand that not all tissues are suitable for Immuno-Oncology studies. To support the specific tissue requirements for Immuno-Oncology projects, we have available a large range of pathologist reviewed FFPE blocks that have been specially selected for the presence of invasive margin, together with accompanying tumor/immune cell PD-L1 scores (Ventana SP-263) and TIL assessment (high/medium/low).

  • PD-L1 data
  • Study of customer specified immune signatures using prevalent platforms
  • Balance of solid tumor and stroma
  • Presence of invasive edge by H&E
  • Qualitative assessment of immune infiltrate
  • Percentage tumor and inflammatory staining PD-L1 positive
  • Follow up data, mutation status, matched RNA/DNA

Samples from Prevalent Tumor Types


>1000 FFPE blocks from prevalent tumour samples with PD-L1 status (Ventana SP-263), TIL assessment and invasive margin, together with mutation status, matched RNA/DNA and follow-up data. Cohorts can be used to build a comprehensive understanding of tumor immune landscape.


  • NSCLC
  • Bladder Cancer
  • Gastric Cancer
  • Head & Neck SCC
  • RCC
  • NHL
  • Prostate Cancer
  • Pancreatic ADC
  • CRC
  • Breast ER+/HER2+ (incl. TNBC)
  • HCC
  • Melanoma
  • Ovarian Cancer

Assays Relevant to Immuno-Oncology


Optimised IHC assay offerings, novel monoplex and duplex assay development, quantitative image analysis and RNAScopeĀ®. Technologies can be applied to:
  • Further immune infiltrate analyses
  • Comparative PD-L1/PD-1 evaluation
  • Study of customer specified immune signatures and novel targets


  • CD20
  • CD3
  • CD4
  • CD68
  • CD73
  • CD8
  • CTLA-4
  • FOXP3
  • GITR
  • Granzyme B
  • ICOS
  • IDO1
  • OX40
  • PD1
  • PDL-1
  • CD45RO
  • TIM-3
  • LAG-3

Applications for FFPE blocks and TMAs

Advanced tissue biomarker dependent I/O drug development enables your team to accelerate translation to the clinic.

  • Expression, distribution and heterogeneity of novel I/O targets across multiple disease settings
  • Examine novel I/O target expression in relation to tumor immune microenvironment e.g. checkpoint inhibitors
  • Spatial relationships of I/O in tumor microenvironment
  • Relate novel I/O target expression to tumor mutation status
  • Identify disease segments most likely to respond toimmunotherapy
  • Co-expression of I/O targets for rational immunotherapy combinations
  • Biomarker development for patient selection

Inquire Today

Inquiry Item Removed. Undo
  • No products in the cart.